Drug intelligence / Profile preview

GT08

Development stage: Discontinued
Lead developer: Synergy Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

GT08 is an investigational non-antibiotic combination regimen developed by Synergy Pharmaceuticals for **Helicobacter pylori infection**. The exploratory Phase 1/2 program described GT08 as using lauric acid as the primary topical antimicrobial component, combined with omeprazole and the mucolytic agent n-acetylcysteine. The intended approach was to reduce gastric acidity with omeprazole and disrupt protective gastric mucus with n-acetylcysteine, enabling lauric acid to act against *H. pylori* in the stomach. The registered clinical study was terminated.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)MUC2 (Mucin-2)

Beyond the preview

Go deeper on GT08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT08.

Explore the full profile